Anzeige

Archive

Platelet receptors as therapeutic targets: Past, present and future

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: https://doi.org/10.1160/TH16-12-0911
Issue: 2017: Issue 7 2017 (pp. 1217-1454)
Pages: 1249-1257
Ahead of Print: 2017-06-09

Platelet receptors as therapeutic targets: Past, present and future

J. Jamasbi (1), K. Ayabe (2), S. Goto (2), B. Nieswandt (3), K. Peter (4), W. Siess (1, 5)

(1) Institute for the Prevention of Cardiovascular Diseases, LMU Munich, Munich, Germany; (2) Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Japan; (3) Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany; (4) Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; (5) DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany

Keywords

Antiplatelet agents, GP IIb/IIIa, GP VI, PAR-1, GP Ibα

Summary

Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ibα, and directed against GPVI, GPIIb/IIIa (integrin αIIbβ3), the thrombin receptor PAR-1, and the ADP receptor P2Y12. The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.

You may also be interested in...

1.

Online Supplementary Material

A. Mojica Muñoz (1), J. Jamasbi (1), K. Uhland (2), H. Degen (2), G. Münch (2), M. Ungerer (2), R. Brandl (3), R. Megens (1, 4), C. Weber (1, 5), R. Lorenz (1), W. Siess (1, 5)

Thromb Haemost 2017 117 8: 1651-1659

https://doi.org/10.1160/TH16-11-0856

2.
Thomas A. Haas

Thromb Haemost 2008 99 1: 96-107

https://doi.org/10.1160/TH07-08-0498

3.

P. C. Armstrong (1), K. Peter (1)

Thromb Haemost 2012 107 5: 808-814

https://doi.org/10.1160/TH11-10-0727